1. Introduction
===============

Autoinflammatory diseases (AIDs) are a cluster of diseases characterized by the aberrant activation of innate immunity. Familial Mediterranean fever (FMF) is 1 of the prototypes of AIDs. In light of the contribution of interleukin-1 (IL-1) to the pathogenesis, and therapeutic responsiveness to IL-1 antagonism, adult onset Still\'s disease (AOSD) has been advocated as being on the spectrum of AIDs in recent years.

FMF features recurrent brief episodes of inflammation which manifests as fever, synovitis, and serositis, and/or amyloidosis, and is associated with mediterranean fever (MEFV) gene mutations.^\[[@R1]\]^ On the other hand, AOSD is characterized by fever, rash, synovitis, and/or hyperferritinemia.^\[[@R2]\]^ These 2 diseases have overlapping features, although FMF has been regarded as being more prevalent in the Mediterranean region. Here we report a Han Chinese AOSD patient with mutations of the MEFV gene who is partially, responsive to colchicine therapy.

2. Case presentation
====================

A 30-year-old woman, without any previous history of disease, or family history of autoimmune diseases/AIDs, experienced episodic fever reaching 38°C, along with concomitant itchy, evanescent wheals localized at her thighs, trunk, and arms, and polyarthritis involving bilateral hands proximal interphalangeal joints, which lasted for 3 to 4 days each time, since 2 years ago. She denied significant body weight loss or night sweats. These symptoms became more frequent, and each time lasted for more than a week. She received oral prednisolone of 0.41 mg/kg/day at another hospital for 5 months, with symptomatic relief. Fifteen months ago, she ceased steroid therapy, and her symptoms flared. Multiple lymphadenopathy in bilateral axillae developed, and a biopsy showed no malignancy. She then underwent Chinese herbal therapy but her symptoms persisted. Then she visited our department.

Upon physical examination, her body temperature was 39.0°C, heart rate 117 beats per minute, respiratory rate 20 per minute, and blood pressure 107/65 mmHg. She appeared well-developed and well-nourished. Her cardiac and pulmonary examination discovered no abnormalities. Joint examination revealed arthritis of her bilateral hands at the 3rd, 4th and 5th proximal interphalangeal joints. Multiple erythematous wheals in the bilateral thighs and legs were also discovered.

The laboratory examination results at the presentation are demonstrated in Table [1](#T1){ref-type="table"}. Leukocytosis, elevated liver function test, and C-reactive protein were noted. Hyperferritinemia (ferritin: 2295 ng/mL) was also noted once. An abdominal sonographry revealed mild hepatosplenomegaly. Hepatitis markers for hepatitis B, and hepatitis C, and a blood polymerase chain reaction test for both cytomegalovirus, and Epstein-Barr virus were all negative. A liver biopsy showed lobular hepatitis with increased eosinophils infiltration, which was compatible with drug-related hepatitis. The Chinese herbal regimen was discontinued, and her liver function gradually recovered. A gallium scan showed diffusely, increased gallium uptake in the skeleton. However, a bone marrow biopsy excluded the presence of hematological malignancy. Although she possessed a positive anti-SSA antibody, she denied having symptoms such as dry eyes, or dry mouth, while a Schimer\'s test result was within normal limits. Consequently, a diagnosis of Sjogren\'s syndrome was waived. According to Yamaguchi\'s criteria,^\[[@R3]\]^ she was diagnosed with AOSD, and initially, received aceclofenac 100 mg once daily, prednisolone 5 mg twice daily, and cyclosporine 25 mg twice daily. Ten days later, the patient had no fever, her skin rashes had improved greatly, but the arthritis in the small joints of her hands mildly improved. Due to some atypical manifestations, she received MEFV gene mutation testing by Sanger sequencing on 3500 Applied Biosystems Genetic Analyzers, which discovered 2 heterozygous non-synonymous mutations in exon 2 (c.329T\>C \[p.Leu110Pro, L110P\], and c.442G\>C \[p.Glu148Gln, E148Q\]) (Fig. [1](#F1){ref-type="fig"}). Afterwards we ceased all medications, and prescribed colchicine 1 mg twice daily for 21 days. Her arthritis became well-controlled after the colchicine prescription was implemented. However, a low grade fever, and wheals re-appeared. We then added prednisolone 5 mg twice daily, and cyclosporine 25 mg twice daily again for a month but the efficacy was poor. A monthly, intravenous tocilizumab at 4 mg/kg was administered, and her symptoms resolved a month later. Tocilizumab was continually, administered each month, and the doses of corticosteroid, colchicine, and cyclosporine were gradually tapered.
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Laboratory values at the presentation.
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![Sequence analysis of the MEFV exon 2 demonstrated 2 heterozygous mutations, A. c.329T\>C (L110P) and B. c.442G\>C (E148Q), in the blood sample obtained from the patient. MEFV = mediterranean fever.](medi-97-e0333-g002){#F1}

3. Discussion and Conclusions
=============================

AOSD is an inflammatory disorder characterized by quotidian fever lasting more than a week, along with arthritis, sore throat, and an evanescent rash. Atypical manifestations such as urticaria, and urticaria-like eruptions may also appear. Our patient\'s clinical manifestations fulfilled the Yamaguchi\'s criteria,^\[[@R3]\]^ and the patient was diagnosed with AOSD. FMF is characterized by recurrent, short (typically 2--4 days), self-limiting fever episodes, along with abdominal, chest, joint, and/or skin involvement. Typically, it can be treated with colchicine. FMF is autosomal recessive, and associated with MEFV gene mutations. People with MEFV mutations can be found around the Mediterranean region. A few reports have described MEFV mutations in other Asian ethnic groups,^\[[@R4]--[@R6]\]^ including Chinese. MEFV mutation can also be detected in autoimmune diseases such as systemic lupus erythematosus,^\[[@R7],[@R8]\]^ and rheumatoid arthritis,^\[[@R9],[@R10]\]^ with its association with clinical phenotypes being inferred. The c.329T\>C and c.442G\>C mutations in our patient, have been recognized as variants of uncertain or mild significance in FMF.^\[[@R11],[@R12]\]^ Three studies have illustrated MEFV mutations in AOSD patients (Table [2](#T2){ref-type="table"}),^\[[@R13]--[@R15]\]^ and discovered some MEFV mutations potentially, predisposed to the development of AOSD and affecting its clinical phenotypes. However, response to colchicine treatment has not been mentioned in these studies.

###### 

Studies describing MEFV mutations in patients with AOSD.
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Colchicine potentially, exerts its efficacy in FMF through its inhibition of the inflammasome/IL-1βpathway, and is generally safe, and well-tolerated.^\[[@R16]\]^ The patient\'s clinical manifestations did not fulfill the Tel-Hashomer diagnostic criteria for FMF.^\[[@R17]\]^ However, the patient reported a good response to colchicine for treatment of her arthritis, which was refractory to nonsteroidal anti-inflammatory drugs (NSAIDs), and low dose corticosteroids. Could this be explained by the patient\'s MEFV gene mutations? We could not give a definite answer.

In conclusion, MEFV mutations may exist in AOSD patients, and colchicine treatment might be useful in their management. More studies in the Han Chinese population are needed.
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